Clinical data | |
---|---|
Other names | SAGE-718 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
KEGG | |
Chemical and physical data | |
Formula | C26H41F3O2 |
Molar mass | 442.607 g·mol−1 |
Dalzanemdor ( INN; [1] development code SAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment. [2] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. [3] Dalzanemdor is an analog of the neurosteroid 24S-hydroxycholesterol. [3]
As of 2022, dalzanemdor is in Phase II clinical trials [3] for Alzheimer's disease, [4] [5] [6] Parkinson's disease, and Huntington's disease. [7] [8]